Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Tenkasi (previously Orbactiv)“
Suchtreffer
Begriffe & Kennungen
Tenkasi (previously Orbactiv) · 4.5 · Oritavancin binds to and prevents the action of the phospholipid reagents which activate coagulation in common
Eintrag öffnenTenkasi (previously Orbactiv) · 4.5 · Prothrombin time (PT) Up to 12 hours International normalized ratio (INR) Up to 12 hours Activated partial thr
Eintrag öffnenTenkasi (previously Orbactiv) · 4.5 · Prothrombin time (PT) Up to 12 hours International normalized ratio (INR) Up to 12 hours Activated partial thr
Eintrag öffnenTenkasi (previously Orbactiv) · 4.5 · Substances metabolised by cytochrome P450
Eintrag öffnenTenkasi (previously Orbactiv) · 4.5 · Substances metabolised by cytochrome P450
Eintrag öffnenTenkasi (previously Orbactiv) · 4.5 · Table 1: Coagulation tests affected by oritavancin Assay Duration of interference
Eintrag öffnenTenkasi (previously Orbactiv) · 4.5 · Table 2: Coagulation tests affected by oritavancin Assay Duration of interference
Eintrag öffnenTenkasi (previously Orbactiv) · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenTenkasi (previously Orbactiv) · 4.6 Fertility, pregnancy and lactation · 2
Eintrag öffnenTenkasi (previously Orbactiv) · 4.8 Undesirable effects · 1
Eintrag öffnenTenkasi (previously Orbactiv) · 4.8 Undesirable effects · 2
Eintrag öffnenTenkasi (previously Orbactiv) · 4.8 · 21 Uncommon Leucocytoclastic vasculitis, angioedema, erythema multiforme, flushing Musculoskeletal and connect
Eintrag öffnenTenkasi (previously Orbactiv) · 4.8 · 7 Respiratory, thoracic and mediastinal disorders Uncommon Bronchospasm, wheezing, dyspnoea* Rare Hypoxia* Gas
Eintrag öffnenTenkasi (previously Orbactiv) · 4.8 · Adverse reactions for oritavancin from the pooled Phase 3 ABSSSI clinical trials with single dose oritavancin
Eintrag öffnenTenkasi (previously Orbactiv) · 4.8 · Adverse reactions for oritavancin from the pooled Phase 3 ABSSSI clinical trials with single-dose oritavancin
Eintrag öffnenTenkasi (previously Orbactiv) · 4.8 · Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1//1 000 to <1/100); rar
Eintrag öffnenTenkasi (previously Orbactiv) · 4.8 · Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare
Eintrag öffnenTenkasi (previously Orbactiv) · 4.8 · Paediatric population
Eintrag öffnenTenkasi (previously Orbactiv) · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenTenkasi (previously Orbactiv) · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnen